Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Synthesis, Characterization, Molecular Docking, and Biological Activities of Coumarin–1,2,3-Triazole-Acetamide Hybrid Derivatives Publisher Pubmed



Sepehri N1 ; Mohammadikhanaposhtani M2 ; Asemanipoor N3 ; Hosseini S4 ; Biglar M3 ; Larijani B3 ; Mahdavi M3 ; Hamedifar H5 ; Taslimi P6 ; Sadeghian N7 ; Gulcin I7
Authors

Source: Archiv der Pharmazie Published:2020


Abstract

Coumarins and their derivatives are receiving increasing attention due to numerous biochemical and pharmacological applications. In this study, a series of novel coumarin–1,2,3-triazole-acetamide hybrids was tested against some metabolic enzymes including α-glycosidase (α-Gly), α-amylase (α-Amy), acetylcholinesterase (AChE), butyrylcholinesterase (BChE), human carbonic anhydrase I (hCA I), and hCA II. The new coumarin–1,2,3-triazole-acetamide hybrids showed Ki values in the range of 483.50–1,243.04 nM against hCA I, 508.55–1,284.36 nM against hCA II, 24.85–132.85 nM against AChE, 27.17–1,104.36 nM against BChE, 590.42–1,104.36 nM against α-Gly, and 55.38–128.63 nM against α-Amy. The novel coumarin–1,2,3-triazole-acetamide hybrids had effective inhibition profiles against all tested metabolic enzymes. Also, due to the enzyme inhibitory effects of the new hybrids, they are potential drug candidates to treat diseases such as epilepsy, glaucoma, type-2 diabetes mellitus (T2DM), Alzheimer's disease (AD), and leukemia. Additionally, these inhibition effects were compared with standard enzyme inhibitors like acetazolamide (for hCA I and II), tacrine (for AChE and BChE), and acarbose (for α-Gly and α-Amy). Also, those coumarin–1,2,3-triazole-acetamide hybrids with the best inhibition score were docked into the active site of the indicated metabolic enzymes. © 2020 Deutsche Pharmazeutische Gesellschaft
Related Docs
View other Related Docs
1. Novel Tacrine-1,2,3-Triazole Hybrids: In Vitro, in Vivo Biological Evaluation and Docking Study of Cholinesterase Inhibitors, European Journal of Medicinal Chemistry (2017)
2. Hetero-Annulated Coumarins As New Ache/Buche Inhibitors: Synthesis and Biological Evaluation, Medicinal Chemistry Research (2016)
3. New 4-Phenylpiperazine-Carbodithioate-N-Phenylacetamide Hybrids: Synthesis, in Vitro and in Silico Evaluations Against Cholinesterase and Α-Glucosidase Enzymes, Archiv der Pharmazie (2022)
Experts (# of related papers)
View all Related Experts
Mohammad Mahdavi (15)
Bagher Larijani (13)
Other Related Docs
4. 1-Phenyl-Β-Carboline-3-Carboxamide-1,2,3-Triazole-N-Phenylacetamide Hybrids As New Α-Glucosidase Inhibitors, Scientific Reports (2025)
5. Novel Quinazolin–Sulfonamid Derivatives: Synthesis, Characterization, Biological Evaluation, and Molecular Docking Studies, Journal of Biomolecular Structure and Dynamics (2022)
6. Synthesis of New 3-Arylcoumarins Bearing N-Benzyl Triazole Moiety: Dual Lipoxygenase and Butyrylcholinesterase Inhibitors With Anti-Amyloid Aggregation and Neuroprotective Properties Against Alzheimer’S Disease, Frontiers in Chemistry (2022)
7. Design of New Α-Glucosidase Inhibitors Based on the Bis-4-Hydroxycoumarin Skeleton: Synthesis, Evaluation, and in Silico Studies, Scientific Reports (2024)
8. Novel Diazen-Bis(Phenoxy-1,2,3-Triazole-N-Phenylacetamide) Derivatives As Potent Anti-Cholinesterase, Anti-Α-Glycosidase and Anti-Α-Amylase Agents: In Vitro and in Silico Evaluations, Journal of Molecular Structure (2025)
9. Design, Synthesis, and Α-Glucosidase-Inhibitory Activity of Phenoxy-Biscoumarin–N-Phenylacetamide Hybrids, Archiv der Pharmazie (2021)
10. New Acridine-9-Carboxamide Linked to 1,2,3-Triazole-N-Phenylacetamide Derivatives As Potent Α-Glucosidase Inhibitors: Design, Synthesis, in Vitro, and in Silico Biological Evaluations, Medicinal Chemistry Research (2020)
11. Cinnamic Acid Conjugated With Triazole Acetamides As Anti-Alzheimer and Anti-Melanogenesis Candidates: An in Vitro and in Silico Study, Scientific Reports (2025)
12. Synthesis and Anticholinergic Activity of 4-Hydroxycoumarin Derivatives Containing Substituted Benzyl-1,2,3-Triazole Moiety, Chemical Biology and Drug Design (2015)
13. In Vivo Anti-Hyperglycemic Activity and Toxicity Evaluation of Two Bis-Coumarin Derivative As Potential Α-Glucosidase Inhibitors, Journal of Diabetes and Metabolic Disorders (2025)
14. New 1E,1′E-Hydrazine-Bis(Phenoxy-1,2,3-Triazol-Acetamide) Derivatives As Potent Inhibitors Against Acetylcholinesterase, Butyrylcholinesterase, and Α-Glucosidase, RSC Advances (2025)
15. Design, Synthesis, in Vitro, and in Silico Biological Evaluations of Coumarin-Indole Hybrids As New Anti-Α-Glucosidase Agents, BMC Chemistry (2022)
16. Development of Coumarin Tagged 1,2,3-Triazole Derivatives Targeting Α-Glucosidase Inhibition: Synthetic Modification, Biological Evaluation, Kinetic and in Silico Studies, Journal of Molecular Structure (2023)
17. 3-Aryl Coumarin Derivatives Bearing Aminoalkoxy Moiety As Multi-Target-Directed Ligands Against Alzheimer's Disease, Chemistry and Biodiversity (2019)
18. Design, Synthesis, Characterization, Enzymatic Inhibition Evaluations, and Docking Study of Novel Quinazolinone Derivatives, International Journal of Biological Macromolecules (2021)
19. Design, Synthesis and Biological Evaluation of Novel Phthalimide-Schiff Base-Coumarin Hybrids As Potent Α-Glucosidase Inhibitors, Chemical Papers (2020)
20. Design, Synthesis, in Vitro and in Silico Biological Assays of New Quinazolinone-2-Thio-Metronidazole Derivatives, Journal of Molecular Structure (2021)